Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.57 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.57 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
| ▸ | SRC | P12931 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19915930 | 0.87 | FGFR1 (0.62) | HTTFGFR1ALDH1A1SRC | |
| SCHEMBL19915601 | 0.86 | CYP1A2 (0.45) | HTTFGFR1ALDH1A1HPGDMAPK1 | |
| SCHEMBL2646769 | 0.81 | HTT (0.59) | HTTFGFR1ALDH1A1HPGD | |
| SCHEMBL29145142 | 0.80 | HTT (0.68) | HTTFGFR1ALDH1A1 | |
| SCHEMBL30723122 | 0.80 | HTT (0.68) | HTTFGFR1ALDH1A1 | |
| SCHEMBL19848149 | 0.80 | HTT (0.62) | HTTFGFR1ALDH1A1HPGDMAPK1 | |
| SCHEMBL23846263 | 0.79 | FGFR1 (0.76) | HTTFGFR1ALDH1A1HPGDMAPK1 | |
| SCHEMBL15638778 | 0.78 | HPGD (0.45) | HTTFGFR1ALDH1A1HPGDMAPK1 | |
| SCHEMBL20698049 | 0.78 | HTT (0.65) | HTTFGFR1ALDH1A1HPGDMAPK1 | |
| SCHEMBL12138910 | 0.77 | HTT (0.64) | HTTFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| EP-3467930-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| EP-3279997-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | Asahi Kasei Kabushiki Kaisha (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | HTT 1107/4885FGFR1 1543/4885ALDH1A1 3497/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | HTT 1107/4885FGFR1 1543/4885ALDH1A1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.